The present study focuses on the impact of age at menarche on body composition development during adulthood. With 459 healthy middle-class women between 18 and 67 years (x ฯญ 41.5) the association between age at menarche and body composition was tested. Body composition, described by absolute and rel
Determinants of serum sclerostin in healthy pre- and postmenopausal women
โ Scribed by Mohammed-Salleh M Ardawi; Hanan A Al-Kadi; Abdulrahim A Rouzi; Mohammed H Qari
- Publisher
- American Society for Bone and Mineral Research
- Year
- 2011
- Tongue
- English
- Weight
- 165 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0884-0431
- DOI
- 10.1002/jbmr.479
No coin nor oath required. For personal study only.
โฆ Synopsis
Sclerostin is a secreted Wnt antagonist produced almost exclusively by osteocytes that regulates bone mass. However, there is currently limited information on the determinants of sclerostin in a large population-based study. The main objectives of the present study were to: (1) establish reference normative interval values for serum sclerostin in randomly selected healthy premenopausal women; (2) study the changes in serum sclerostin in relation to age in premenopausal and postmenopausal women and the factors that may influence bone turnover; and (3) determine the effect of menopausal status on serum sclerostin. A total of 1803 women were studied (including [n ยผ 1235] premenopausal, and [n ยผ 568] postmenopausal women, respectively, aged 20 to 79 years). A total of 443 healthy premenopausal women (aged 35 to 45 years) were used to establish reference normative intervals for serum sclerostin. All women studied were medically examined and had their bone mineral density values obtained for the lumbar spine (L 1 -L 4 ) and femoral neck according to a detailed inclusion criteria. In all women, values of serum sclerostin increased with increasing age up to the age of 45 years, and remained increased in postmenopausal women. Significant increases were evident in serum sclerostin in postmenopausal women with increasing years since menopause. Using stepwise multiple linear regression analysis, several variables were identified as determinants of serum sclerostin, including age, parathyroid hormone, estradiol (E 2 ), and follicle-stimulating hormone (FSH) for premenopausal women; age, FSH, and E 2 for postmenopausal women; and age, serum osteocalcin, FSH, and E 2 in the entire sample studied. Further studies are needed to establish the potential role of this increase in mediating the known age-related impairment in bone formation.
๐ SIMILAR VOLUMES
Letrozole is a new non-steroidal inhibitor of the aromatase enzyme system. It is currently under development for the treatment of postmenopausal women with advanced breast cancer. Absolute bioavailability of letrozole when given orally as one 2ยด5 mg ยฎlm-coated tablet in comparison to the same dose g
## Abstract Breast cancers in younger, premenopausal women are more likely to exhibit an adverse prognostic profile (including negative steroid hormone receptors and a high rate of cellular proliferation) and poor outcome than breast cancers in postmenopausal women. It has been hypothesized that th
A high-performance liquid chromatographic (HPLC) method with fluorescence detection (! ex = 280 nm; ! em = 410 and 312 nm) in combination with a post-column on-line photochemical derivatization is described for the determination of equilin and equilenin in urine from normal postmenopausal women afte
## BACKGROUND. This study was undertaken to assess the correlation between CA 125 elevation, a past history of cancer, and future risk of a diagnosis of cancer among asymptomatic postmenopausal women. ## METHODS. The subjects consisted of a study group of 771 women with elevated CA125 (ี30 U/mL)